newsfilter
← Latest News
GlobeNewswire·

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now